Featured Content

H. Jack West, MD
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

Biodesix Launches GeneStrat Targeted Liquid Biopsy Mutation Test for Patients with Advanced Lung Cancer

(Biodesix) May 21, 2015 - Biodesix, Inc. today announced the launch of GeneStrat™, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC).

Commentary: There is no question that the ability to do liquid biopsies would be a great help in managing lung cancer. I would...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

New Drugs From Bristol, Merck at Forefront of Cancer Meeting

(Reuters) May 28, 2015 - New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body's immune system to fight cancer can be used.
read article »

Cancer Is Getting More Expensive, Forcing Doctors to Take Notice

(Bloomberg) May 28, 2015 - Gale Tickner doesn’t even know how much money she owes these days -- it could be $100,000, it could be $200,000.
read article »

Galena Biopharma Rises on Cancer Therapy Study

(Yahoo! Finance/Associated Press) May 27, 2015 - Shares of Galena Biopharma rose Wednesday after the cancer drug developer reported promising data from a clinical study of a second potential cancer vaccine.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Biodesix Launches GeneStrat Targeted Liquid Biopsy Mutation Test for Patients with Advanced Lung Cancer (Biodesix)

There is no question that the ability to do liquid biopsies would be a great help in managing lung cancer. I would...posted by: H. Jack West, MD

Community Oncology Alliance Pharmacy Associations (COPA) Names Advisory Board (COA)

Thank you to COA for recognizing the need to focus on the care of patients being treated with oral oncology products....posted by: Jeff Patton, M.D.

Boehringer Ingelheim Showcases Expanding Presence in Lung Cancer at ASCO 2015 with New Data Including Presentation of Afatinib Overall Survival Results for Squamous Cell Carcinoma of the Lung (Yahoo! News)

While the comparison of afatinib to erlotinib in squamous NSCLC (and presumably all EGFR wild type) is of some...posted by: H. Jack West, MD

New Blood Tests, Liquid Biopsies, May Transform Cancer Care (ABC News/Associated Press)

Circulating tumor cells research will most likely become the next area of explosive research in this arena. CTC...posted by: Winston Wong, PharmD

St. Gallen International Breast Cancer Guidelines for the Third Time Distinguish Oncotype DX(R) as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit (Morningstar)

While the consensus of the panel noted the ability of OncoType to predict chemotherapy benefit, it did fall on...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Seattle Genetics has 3 new jobs posted.


Bayer has 11 jobs posted.


Circassia has 1 job posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CTIC +7.37%
ADXS +5.25%
GTXI +4.39%
NBS -22.43%
CBMG -6.93%
AVEO -5.56%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: Q2 2015
Company: Exelixis
Product: cabozantinib

Date: August 11, 2015
Company: Roche / Genentech & Exelixis
Product: cobimetinib

Date: Q3 2015
Company: AstraZeneca PLC
Product: Iressa® (gefitinib)

See All OBR Radar items»